title: Tyrosine kinase chimeras for antigen-selective T-body therapy.
abstract: Protein tyrosine kinases (PTKs) transmit activation signals in almost every cell type, including immune effector cells. The aberrant or constitutive activation of PTKs can often cause neoplastic transformation. The use of chimeric receptors based on PTKs may enable us to elucidate the signaling pathways of normal immune cells and other cell types, and the abnormal events that can lead to malignant transformation. In this review, we focus on antigen specific chimeric PTKs in which antibody-derived scFv are joined to the Syk family of PTKs. These chimeric receptors yielded reagents that can selectively redirect immune effector cells and specifically activate them to produce cytokines or lyse their target. The advantages of using such PTK-based chimeras to redirect lymphocytes to tumor targets and their potential as an immunotherapeutic approach to malignant disease is discussed.
authors.affiliation: Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
authors.initials: Z
authors.lastname: Eshhar
authors.initials: CJ
authors.lastname: Fitzer-Attas